Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Arun Azad, PhD
Advertisement
Articles by Arun Azad, PhD
Arun Azad, PhD, discusses the design of the phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses the utility of adding enzalutamide to androgen deprivation therapy in subgroups of men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses the results of the post-hoc analyses of the phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer.
Arun Azad, PhD, discusses unmet needs for men with metastatic hormone-sensitive prostate cancer.
Advertisement
Latest Updated Articles
Dr. Azad on the Design of the ARCHES Trial in mHSPCOctober 20th 2020
Dr. Azad on the Significance of the PROfound Trial in mCRPCOctober 22nd 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 5/31
5